News headlines about Presbia (NASDAQ:LENS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Presbia earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.697450508038 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several research firms have issued reports on LENS. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Presbia in a research note on Wednesday, December 20th. Zacks Investment Research upgraded Presbia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Presbia presently has an average rating of “Hold” and a consensus price target of $9.67.
Shares of Presbia (NASDAQ LENS) traded down $0.13 during mid-day trading on Friday, hitting $3.06. The stock had a trading volume of 3,209 shares, compared to its average volume of 8,532. Presbia has a 1-year low of $1.86 and a 1-year high of $7.14. The stock has a market capitalization of $52.39, a price-to-earnings ratio of -2.55 and a beta of -0.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.02 and a quick ratio of 2.94.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/18/presbia-lens-earns-daily-coverage-optimism-score-of-0-04.html.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.